Takeda M, Shimokawa M, Nakamura A, Nosaki K, et al. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemot Lung Cancer 2023;177:44-50.
PMID: 36731290